Core Viewpoint - Medtronic is positioning itself as a strong player in the robotic surgery market while maintaining a solid foundation in the medical device industry, with a focus on growth and innovation. Company Overview - Medtronic has a forward-looking price-to-earnings (P/E) ratio of 16.3, slightly below its five-year average of 16.7, indicating a compelling valuation [2] - The company has a dividend yield of 2.9% and has increased its dividend for 48 consecutive years, showcasing its commitment to returning value to shareholders [4] - Medtronic's payout ratio is approximately 79%, suggesting room for further dividend growth and sustainability [5] Business Operations - Medtronic operates in various treatment areas, including surgery, endoscopy, cardiac ablation, neurovascular disorders, neuromodulation, pelvic health, gastric therapies, and cranial and spinal technologies [5] - The company has over 41,000 active patent matters and employs more than 13,600 scientists and engineers across 150 countries [6] - Medtronic treats over 70 health conditions and is conducting more than 174 active clinical trials, with an annual research and development expenditure of around $2.7 billion [6] Recent Performance - In its recently reported third quarter, Medtronic achieved an 8.7% year-over-year revenue increase and received FDA approval for its Hugo robotic surgery system [8] - CEO Geoff Martha emphasized the company's focus on unlocking new markets and investing in high-growth opportunities to accelerate performance [8] Strategic Moves - Medtronic is spinning off its diabetes division, aiming for a valuation close to $8 billion, to concentrate on faster-growing business segments [7]

February 25, 2026 11:27 AM GMT Brain Computer Interfaces | North America Neuralink Hits 21 Patients; Precision/Medtronic Partnership; Altman's Merge Labs We highlight some key happenings across the BCI industry: Neuralink is scaling implants and plans mass production in 2026, Sam Altman's Merge Labs emerged from stealth with OpenAI backing, Precision and Medtronic reach agreement to develop joint-system, China expected to add BCI to Five Year Plan. Morgan Stanley does and seeks to do business with companies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Commission File Number 001-36820 Identification No.) Building Two, Parkmore Business Park West Galway, Ireland (Address of principal executive offices) +353 1 438-1700 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R.S. Employer | Title of each cla ...

MiniMed announces launch of IPO roadshow [Accessibility Statement] Skip NavigationGALWAY, Ireland, Feb. 24, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced that it has launched a roadshow for the initial public offering (IPO) of 28,000,000 shares of its common stock. The proposed offering is part of Medtronic's previously announced plan to separate its Diabetes business into an independent public company.The IPO price is currently ex ...

Group 1 - Medtronic's MiniMed Group is targeting to raise up to $784 million in its initial public offering (IPO) in the United States [1] - The IPO is part of Medtronic's strategy to enhance its diabetes business and expand its market presence [1]

Core Viewpoint - Medtronic is highlighted as an attractive investment primarily due to its impressive dividend track record, having increased dividends for 48 consecutive years, positioning it to potentially join the ranks of Dividend Kings [1][3]. Dividend Program - The company has a remarkable history of increasing dividends, which is a strong indicator of its reliability and business stability [3][7]. - Achieving 48 years of consecutive dividend increases is a significant accomplishment, suggesting that Medtronic is a steady and reliable business that performs well regardless of economic conditions [4][7]. Financial Performance - Medtronic's revenue growth is consistent, supported by its extensive portfolio in the healthcare industry, although it may not be exceptionally high [6]. - The company has a gross margin of 67.46% and a dividend yield of 2.92%, indicating strong financial health [6]. Business Strategy - Management is divesting from its low-margin diabetes-care business, which is expected to enhance operating margins and profits [8]. - New product launches, such as the Hugo robot-assisted surgery system and pulse-field ablation treatment, are anticipated to drive sales growth in the medium term [9]. Market Position - Medtronic is one of the largest medical device companies globally, with a market capitalization of $124 billion [10]. - The stock is particularly appealing to income-seeking investors rather than those looking for high-growth opportunities [9].

Core Insights - Medtronic is a consistent dividend payer with a 48-year history of increasing its dividend, making it a unique player in the healthcare stock sector [1][7] - The company operates in a recession-resistant market, providing essential medical devices and treatments that are often non-negotiable for patients [2] - Medtronic has only experienced two declines in annual revenue since 2000, with a 5.4% drop in fiscal year 2020 due to the COVID pandemic and a 1.4% decrease in 2023 attributed to currency fluctuations and supply chain issues [4] - The company has four strong business units: cardiovascular, medical-surgical, neuroscience, and diabetes, although the diabetes unit is set to be spun off [5] - Medtronic has maintained annual net income for over 60 years, showcasing its financial stability despite some fluctuations in profitability [6] - The current dividend yield is nearly 3%, which is more than double the average yield of S&P 500 stocks, highlighting the company's commitment to returning value to shareholders [7] - Despite its strong fundamentals, Medtronic's stock has underperformed the S&P 500 index for several years due to frequent restructuring and competition from other healthcare companies [8] - The company has received FDA clearance for its Hugo robotic-assisted surgery system, indicating potential growth opportunities in the future [10] - Expectations are high for Medtronic to outperform the S&P 500 in the coming years, suggesting a potential investment opportunity [11]

Company Overview - Medtronic is one of the world's largest medical device companies with a diversified portfolio across cardiovascular, neuroscience, and medical-surgical sectors [2] - The company is planning to spin off its diabetes business to refocus on its highest-profit and fastest-growing operations, indicating a strategic shift [2] Innovation and Growth - Medtronic has a proven track record of innovation, exemplified by the Hugo surgical robot, which positions the company in a fast-growing medical market [4] - The company is expected to see revenue growth of 5.5% in fiscal 2026, reflecting its strategic focus on growth [7] Dividend Performance - Medtronic has achieved 48 consecutive annual dividend increases, nearing the status of Dividend Kings, which signifies a strong and reliable business model [5] - The current dividend yield is approximately 2.92%, which is historically high, indicating the company's commitment to returning value to shareholders [7] Market Position - Medtronic has a market capitalization of $124 billion, with a gross margin of 67.46%, showcasing its financial strength [7] - The stock price currently stands at $96.88, with a day's range between $96.46 and $97.86, reflecting market activity [7]

Medtronic PLC (NYSE:MDT) posted better-than-expected earnings for the third quarter on Tuesday.The company posted adjusted EPS of $1.36, beating market estimates of $1.33. The company’s quarterly sales came in at $9.017 billion, versus expectations of $8.905 billion.Medtronic affirmed its FY2026 adjusted EPS guidance of $5.62-$5.66, versus market estimates of $5.65.Medtronic shares rose 0.1% to $96.45 in pre-market trading.These analysts made changes to their price targets on Medtronic following earnings an ...

Market Overview - Futures are trading higher after a sluggish start to the holiday-shortened trading week, with all major indices ending the day modestly higher [2] - The Nasdaq closed at 22,578, up 0.14%, marking its fifth consecutive week of decline prior to this [2] - The Dow Jones closed at 49,533, up 0.07%, and the S&P 500 closed at 6,843, up 0.10%, while the small-cap Russell 2000 closed down 0.11% at 2,646 [2] Treasury Bonds - Yields on Treasury bonds were slightly higher as sellers took profits after a solid move higher last week [3] - The 30-year bond closed at 4.69%, and the benchmark 10-year note was last seen at 4.06% [3] Oil and Gas - Oil prices decreased after a rise the previous week, with Brent Crude finishing at $67.32, down 1.94%, and West Texas Intermediate at $62.23, down 1.05% [4] - Natural gas prices fell significantly, closing down 6.2% at $3.04 [4] Precious Metals - Gold and Silver experienced declines due to profit-taking and short selling, with Gold recorded at $4,876, down 2.31%, and Silver at $73.36, down 4.16% [5] Earnings and Economic Data - The focus will shift towards economic data as fourth-quarter earnings wrap up with Walmart's report on Thursday [6] - Despite solid earnings for the quarter, ongoing market issues persist, with some analysts suggesting a 10%-15% correction would be beneficial [6]